1. Market Research
  2. > Pharmaceutical
  3. > Therapy
  4. > Oncology Market Trends
Metastatic Cancer Drug Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Cancer Type, Route of Administration, Drug Class, Product, and End User

Metastatic Cancer Drug Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Cancer Type, Route of Administration, Drug Class, Product, and End User

  • April 2022
  • 233 pages
  • ID: 6279450
  • Format: PDF
  • The Insight Partners

Summary

Table of Contents

The metastatic cancer drug market size is projected to reach US$ 68,349.54 million by 2028 from US$ 51,157.97 million in 2021. It is expected to grow at a CAGR of 4.2% from 2021 to 2028. The report highlights trends prevailing in the market and factors driving the metastatic cancer drug market growth.

The growth in the metastatic cancer drug market is attributed to the increasing prevalence of metastatic cancer across the world and rising government initiatives to support research and developments in cancer treatment. However, the high cost of oncology drugs restricts the market.

Metastatic cancer is defined as an advanced cancer stage that spreads to the other body parts, and the drugs used for the treatment of advanced-stage cancer are known as metastatic cancer drugs. These drugs are used through various therapies, such as chemotherapy, immunotherapy, and targeted therapy.

Governments of various countries are introducing missions and programs for quick and effective cancer treatment.In 2016, the US Government launched the Cancer Moonshot with three ambitious goals: To accelerate scientific cancer-related discovery, foster greater collaboration, and improve data sharing.

The cancer patient community and medical researchers responded with tremendous energy and ingenuity to this campaign.On February 2, 2022, the Cancer Moonshot project was relaunched by highlighting new goals of reducing the death rate of cancer by at least 50% over the next 25 years, improving the experience of people and their families living with and surviving cancer, and putting an end to cancer through these efforts.

By focusing on the areas of cancer research and encouraging new investments that are most likely to benefit patients, the Cancer Moonshot has brought together a large community of investigators and clinicians dedicated to expediting research to improve the lives of patients.

In 2020, 2.7 million people in the European Union were diagnosed with the disease, and another 1.3 million people lost their lives to it. The EU has been working to tackle cancer for decades and its actions, for example tobacco control and protection from hazardous substances, have saved and prolonged lives. Europe’s Beating Cancer Plan is the EU’s response to the need for cancer treatment. It reflects a political commitment to leave no stone unturned to take action against cancer. Mobilizing the collective power of the EU to drive change for the benefit of the citizens, the Cancer Plan contains concrete, ambitious actions that will support, coordinate and complement Member States’ efforts to reduce the suffering caused by cancer. Over the coming years, it will focus on research and innovation, tap into the process of digitalization and offer new technologies, and mobilize financial instruments to support the Member States.

The European Medicines Agency introduced and authorized a drug named Trodelvy that exhibits greater benefits than its risks.In January 2021, AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) were granted conditional approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens.

In Europe, over 531,000 breast cancer cases in women are diagnosed per year, with approximately 1 in 5 patients being HER2-positive. The impact of the disease is significant, with breast cancer responsible for more than 141,000 deaths annually in Europe.

Based on cancer type, the metastatic cancer drug market is segmented into breast cancer, lung cancer, liver cancer, hematological cancer, brain cancer, prostate cancer, pancreatic cancer, and others.The breast cancer segment accounted for the largest market share in 2021 and is anticipated to register the highest CAGR during the forecast period.

Based on the route of administration, the metastatic cancer drug market is segmented into intravenous, intramuscular, oral, and others.The intravenous segment accounted for the largest market share in 2021 and is expected to register the highest CAGR during the forecast period.

Based on drug class, the metastatic cancer drug market is segmented into HER2 inhibitors, immune checkpoint inhibitors, PARP inhibitors, kinase inhibitors, and others.The PARP inhibitors segment accounted for the largest market share in 2021.

However, the HER2 inhibitors segment is expected to register the highest CAGR during the forecast period. Based on product, the metastatic cancer drug market is bifurcated into branded and generics and biosimilars. The branded segment accounted for a larger market share in 2021. However, the generics & biosimilars segment is estimated to register a higher CAGR during the forecast period. Based on end user, the metastatic cancer drug market is segmented into hospitals, specialty clinics, and others. The hospital segment accounted for the largest share in 2021, whereas the specialty clinic segment is estimated to register the highest CAGR during the forecast period.

With regular screening, consolations, and treatments, the market for metastatic cancer drugs in North America was constantly growing before the pandemic.The first wave of the COVID-19 crisis disrupted the consultations, follow-ups, and screenings of oncological cases.

Countries such as the US and Canada reported the highest number of COVID-19 positive cases.The US-registered highest number of deaths due to the COVID-19 crisis.

The chaotic situation created in the healthcare industry across the countries led to a reduced number of consultations and a smaller number of cancer cases diagnosed.For instance, international efforts suggest that the diagnoses of cancers were reduced by 40% between March 9 and May 17, 2020, compared to diagnoses averaged over the same period between 2018 and 2019.

The disruption of clinical trials and drug supply to patients resulted from the pandemic crisis, thus hampering the metastatic cancer drug market.

Various organic and inorganic strategies are adopted by companies in the metastatic cancer drug market.The organic strategies mainly include product launches and product approvals.

Inorganic growth strategies witnessed in the market are acquisitions, collaboration, and partnerships.These growth strategies have allowed the metastatic cancer drug market players to expand their business, enhance their geographic presence, and contribute to the overall market growth.

Additionally, various growth strategies, such as acquisitions and partnerships, helped them strengthen their customer base and extend their product portfolios. A few of the significant developments by key players in the metastatic cancer drug market are listed below.

In January 2022, AbbVie announced that the US FDA granted Breakthrough Therapy Designation (BTD) to investigate the telisotuzumab vedotin (Teliso-V) for the treatment of patients with advanced/metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC) with high levels of c-Met overexpression whose disease has progressed on or after platinum-based therapy.

A few of the major primary and secondary sources referred to while preparing the report on the metastatic cancer drug market are the National Center for Health Statistics (a department of the US Department of Health & Human Services), Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), and Organization for Economic Co-operation and Development (OECD).

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Global Interventional Oncology Market Size, Share & Industry Trends Analysis Report By Cancer Type, By Product Type, By End User, By Regional Outlook and Forecast, 2022 – 2028

  • $ 3600
  • June 2022
  • 242 pages

The Global Interventional Oncology Market size is expected to reach $2.9 billion by 2028, rising at a market growth of 6.2% CAGR during the forecast period. Interventional oncology (IO) is an emerging ...

  • World
  • APAC
  • Oncology
  • Cancer
  • Industry analysis
  • Health Expenditure
  • Diagnostic Imaging Density

ref:plp2022

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on